Washington, DC (January 27, 2025) – Following the inauguration of President Donald Trump, Pharmaceutical Printed Literature Association (PPLA) Board Chairman Dave Joesten issued the following statement urging Robert F. Kennedy Jr., President Trump’s nominee for Health and Human Services (HHS) Secretary, and Dr. Marty Makary, President Trump’s nominee for U.S. Food and Drug Administration (FDA) Commissioner, to prioritize clear and printed Prescribing Information (PI) and Patient Medication Information (PMI) by rescinding two proposed rules.
“We are confident that the new Trump administration will quickly see that the FDA’s proposed rules on PI and PMI were not drafted with patient safety as the top priority,” said Dave Joesten, Board Chairman of PPLA. “We look forward to working with Dr. Makary, Robert F. Kennedy Jr., and the Trump administration to rescind these proposed rules to ensure that all healthcare professionals can deliver care with accessible drug information and that all Americans can avoid medication nonadherence with clear, effective, and printed medication information.”
Previously, the FDA proposed two rules limiting access to printed PI and PMI, the life-saving guidance used by healthcare professionals and patients respectively. The rules would shift PI and PMI to digital-only formats, damaging pharmacy care and threatening many low-income, older, and rural patients without consistent broadband access who can’t access digital resources. The PMI rule would also cost struggling community pharmacies over $1.5 billion and 71 million labor hours annually. Instead, a bipartisan coalition in Congress proposed legislation creating a more effective and printed version of PMI.
The Pharmaceutical Printed Literature Association
Chartered in 2001, the PPLA serves as the voice for our members, advocating for patient safety and risk communication by fighting to keep information on paper and readily accessible for patients and caregivers. This information helps drive the patient involvement model of health care, helping patients get the maximum benefits from the powerful drugs they take while minimizing risk.
For more information about PPLA, click here.